This presents the immune system components required to create vaccine. James Nanotechnologybased vaccines have tremendous opportunities for applications in developing countries.NanoBio holds the exclusive worldwide license from UM on the patented Nanostat technology. Baker to conduct this science and to launch this promising company, says Stephen Forrest, vice president for research. second product, topical treatment for cold sores herpes virus infection, has completed Phase II human clinical trials and is positioned to advance to Phase III trials later this year. UM has licensed the technology exclusively to NanoBio.

Scientists at the institute are exploring applications of this technology took place at UM with funding from the This reaction tears the pathogen membrane, which kills the organism. Preclinical work is underway on mucosal vaccine for the prevention of influenza, anthrax, smallpox and hepatitis This presents the immune system components required to create vaccine. The technology can be adapted for use with almost any infectious agent.There is great promise for vaccines based on this technology because they can be administered without the use of needles or refrigeration, Baker says.

reception set for new provost International travel committee urges caution in response to terror threatMars surface probably cant support lifeReuters will distribute UM consumer surveys UM, Johns Hopkins search together for bipolar geneSpotlight Shining light through the blindsUMDearborn faculty, students study airports economic impactChemistrys Sanford, Mapp honored at White HousePreview of benefits choicesEstrogen probably not the only factor in menopausal bone lossUM ranks high for LGBT studentsStudy demos successful HIVprevention program for Latino youthProfessors nanotech company secures 30M investmentElite national undergrads complete Rackham programUM adopts twofactor authentication to safeguard informationEarly retirement

The technology can be adapted for use with almost any infectious agent.There is great promise for vaccines based on this technology because they can be administered without the use of needles or refrigeration, Baker says. The vaccine work was funded by grants from the National Institute for Allergies and Infectious Diseases and the Bill and Melinda Gates Foundation. Preclinical work on an influenza vaccine that could be applied directly to mucous membranes will begin this fall, followed by clinical development program.

Preclinical work is underway on mucosal vaccine for the prevention of influenza, anthrax, smallpox and hepatitis This presents the immune system components required to create vaccine. In this vaccine work, Bakers team has applied mixture of nanoemulsion and either whole virus or protein directly to the nose of the animals.